Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study
In patients with HR-HER2+ EBC, the neoadjuvant therapy with trastuzumab, pyrotinib, and dalpiciclib has promising activity and manageable toxicity. Further investigation is needed.
Authors
- Xuan Liu (ORCID: https://orcid.org/0000-0002-1206-5501)
- Zhi Xiao
- Haiyan Zhou (ORCID: https://orcid.org/0000-0002-0868-3606)
- Kuansong Wang
- Yu Hu (ORCID: https://orcid.org/0000-0002-4878-3169)
- Nianhua Ding (ORCID: https://orcid.org/0000-0002-6203-8464)
- Wenlong Wang (ORCID: https://orcid.org/0000-0003-4441-6027)
- Jing Cao (ORCID: https://orcid.org/0000-0001-9302-4850)
- Feiyu Chen (ORCID: https://orcid.org/0000-0002-9643-0739)
- Liqiu Liao
- Shayang Luo
- Juan Huang (ORCID: https://orcid.org/0000-0002-5330-8338)
- Yan Li (ORCID: https://orcid.org/0000-0002-2781-2119)
- Na Luo (ORCID: https://orcid.org/0000-0001-8050-2067)
- Xiangyan Liu (ORCID: https://orcid.org/0000-0001-5118-2949)
- Tao Xu (ORCID: https://orcid.org/0000-0001-9806-1335)
- Shouman Wang
Institutions
- Central South University (CN)
- Changsha Medical University (CN)
- Weatherford College (US)
- Xiangyang Central Hospital (CN)
- The Central Hospital of Shaoyang (CN)
- Xiangshan County First People's Hospital (CN)
- Xiangya Hospital Central South University (CN)
- Xiang Yang No.1 People's Hospital (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1097/js9.0000000000003328
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00